Based on our results, we concluded that EphA2, EphA3, EphA4, and EphA5 were down-regulated in BCs, and high expression levels of these genes indicated better RFS, suggesting that EphA2, EphA3, EphA4, and EphA5 act as tumor suppressors in BC and could be new biomarkers for its prognosis. This evidence concerns the gene EPHA2 and breast cancer.